Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease, which ...

BioMarin Pharmaceutical (NASDAQ:BMRN) introduced its longer-term outlook and plans to implement a $500M cost transformation program at its investor day event today. The California-based pharma has ...

The Intersection of AI and Biology in Revolutionizing Healthcare In recent years, the fusion of artificial intelligence (AI) with biological ...

William Blair has initiated coverage on coverage of Bio-Techne Corp TECH with an Outperform rating. Bio-Techne is positioned in high-growth and attractive end-markets, notably cell and gene therapy (C ...